INDGN/SE/2026-27/35

30 July 2026

BSE Limited, Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai- 400001, India. Scrip Code: 544172	National Stock Exchange of India Limited Exchange Plaza, C-1, Block G, Bandra Kurla Complex, Bandra (E), Mumbai - 400 051, India. Trading symbol: INDGN

Dear Sir / Madam,

Subject: Outcome of Board Meeting held on July 30, 2026

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations"), we hereby inform you that the Board of Directors of Indegene Limited at its meeting held on Thursday, July 30, 2026, has, inter alia:

1. Approved unaudited Standalone and Consolidated Financial Results along with Limited Review Report of the Auditors thereon for the quarter ended June 30, 2026.
   The Financial Results along with the Limited Review Report of the Auditors with an unmodified opinion and CFO declaration are enclosed herewith.

2. Approved allotment under ESOP Scheme 2020.

Please be informed that pursuant to the SEBI (Prohibition of Insider Trading) Regulations 2015 and the Company's Code of Conduct for Regulating, Monitoring and Reporting of Trading by Insiders, the Trading Window for dealing in the securities of the Company by its Designated Persons shall reopen with effect from Monday, 03rd August, 2026.

The meeting of the Board of Directors commenced at 05:30 PM (IST) and concluded at 06:15 PM (IST).

The above information will be made available on the website of the Company: https://www.indegene.com/

We request you to kindly take the same on record.

Thanking You

Yours Sincerely,
For Indegene Limited

SRISHTI RAMESH KAUSHIK

Digitally signed by SRISHTI RAMESH KAUSHIK
Date: 2026.07.30 18:39:09 +05'30'

Srishti Ramesh Kaushik
Company Secretary and Compliance Officer
Encl: A/a

Deloitte Haskins & Sells

Chartered Accountants
Prestige Trade Tower, Level 19
46, Palace Road, High
Grounds, Bengaluru – 560 001
Karnataka, India

Tel: +91 (80) 6188 6000
Fax: +91 (80) 6188 6011

INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM CONSOLIDATED FINANCIAL RESULTS

TO THE BOARD OF DIRECTORS OF
INDEGENE LIMITED

1. We have reviewed the accompanying Statement of Consolidated Unaudited Financial Results of **INDEGENE LIMITED** ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group"), for the quarter ended June 30, 2026 ("the Statement") being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations").

2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of Parent's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under Section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

4. The Statement includes the results of the entities as mentioned in Annexure I to this review report.

5. Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

6. The consolidated unaudited financial results includes the interim financial information of 1 subsidiary and 10 step down subsidiaries which have not been reviewed by their auditors, whose interim financial information reflects total revenue of Rs. 413 million for the quarter ended June 30, 2026, total loss after tax of Rs. 12 million for the quarter ended June 30, 2026 and other comprehensive loss of Rs. 18 million for the quarter ended June 30, 2026, as considered in the Statement. According to the information and explanations given to us by the Management, these interim financial information are not material to the Group.

   Our Conclusion on the Statement is not modified in respect of our reliance on the interim financial information certified by the Management.

For **Deloitte Haskins & Sells**
Chartered Accountants
Firm's Registration No. 008072S

Sathya P Koushik
Partner
Membership No.: 206920
UDIN: 26206920XKSBYL3444

Place: Bengaluru
Date: July 30, 2026

Deloitte
Haskins & Sells

Annexure I to Independent Auditor's Review Report on Review of Interim Consolidated Financial Results.

The Consolidated Unaudited Financial Results for the quarter ended June 30, 2026 include financial results of the following companies:

Sr. No.	Company Name	Category	Country of Incorporation
1	Indegene Limited	Parent Company	India
2	ILSL Holdings Inc.	Wholly Owned Subsidiary	USA
3	Indegene Inc.	Step Down Subsidiary	USA
4	Indegene Healthcare Canada Inc.	Step Down Subsidiary	Canada
5	DT Associates Research and Consulting Services Ltd	Step Down Subsidiary	England
6	DT Associates Research and Consulting Inc.	Step Down Subsidiary	USA
7	Cult Health LLC	Step Down Subsidiary	USA
8	Indegene Japan LLC	Step Down Subsidiary	Japan
9	Indegene Healthcare Mexico S DE RL DE CV	Wholly Owned Subsidiary	Mexico
10	Indegene Ireland Limited	Wholly Owned Subsidiary	Ireland
11	Indegene Healthcare Germany GmbH	Step Down Subsidiary	Germany
12	Indegene Fareast Pte Ltd	Step Down Subsidiary	Singapore
13	Indegene Europe LLC	Step Down Subsidiary	Switzerland
14	Indegene Lifesystems Consulting (Shanghai) Co. Ltd.	Step Down Subsidiary	China
15	Indegene Healthcare UK Limited	Step Down Subsidiary	England
16	Trilogy Writing & Consulting GmbH	Step Down Subsidiary	Germany
17	Trilogy Writing & Consulting Limited	Step Down Subsidiary	England
18	Trilogy Writing & Consulting Inc.	Step Down Subsidiary	USA
19	Indegene Spain S.L.U	Step Down Subsidiary	Spain
20	MJL Communications Group Ltd	Step Down Subsidiary	England
21	MJL Advertising Limited	Step Down Subsidiary	England
22	BioPharm Parent Holding, Inc	Step Down Subsidiary	USA
23	BioPharm Communications LLC	Step Down Subsidiary	USA
24	Addressable Health LLC	Step Down Subsidiary	USA
25	Warn and Co Limited	Step Down Subsidiary	England
26	Cake Kommunikations Holding GmbH	Step Down Subsidiary	Austria
27	Cake Kommunikations GmbH (AT)	Step Down Subsidiary	Austria
28	CAKE Kommunikations AG	Step Down Subsidiary	Switzerland
29	Cake Kommunikations GmbH (DE)	Step Down Subsidiary	Germany

INDEGENE LIMITED

CIN No. L73100KA1998PLC102040

Statement of Consolidated Financial Results for the quarter ended 30 June 2026

(All amounts in ₹ millions, except share data and where otherwise stated)

Sl. No.	Particulars	Quarter ended			Year ended
		30 June 2026	31 March 2026	30 June 2025	31 March 2026
		Unaudited	Unaudited (Refer Note 2)	Unaudited	Audited
1	**Income**				
	(a) Revenue from operations	10,631	10,034	7,608	35,105
	(b) Other income (net)	290	108	221	720
	Total income	**10,921**	**10,142**	**7,829**	**35,825**
2	**Expenses**				
	(a) Employee benefits expense	6,591	6,324	4,815	21,977
	(b) Finance costs	64	72	37	193
	(c) Depreciation and amortisation expense	441	418	216	1,264
	(d) Other expenses	2,298	2,074	1,240	6,938
	Total expenses	**9,394**	**8,888**	**6,308**	**30,372**
3	**Profit before exceptional item and tax (1-2)**	**1,527**	**1,254**	**1,521**	**5,453**
4	Exceptional items (net) (refer note 10)	-	(203)	-	(203)
5	**Profit before tax (3+4)**	**1,527**	**1,051**	**1,521**	**5,250**
6	**Tax expense**				
	- Current tax	293	226	284	1,763
	- Deferred tax	72	28	73	(524)
	Total tax expense	**365**	**254**	**357**	**1,239**
7	**Profit for the period/year (5-6)**	**1,162**	**797**	**1,164**	**4,011**
8	**Other Comprehensive Income (OCI), net of taxes**				
	Items that will not be reclassified subsequently to the statement of profit or loss:				
	Remeasurement of defined benefit obligation	(29)	(1)	12	41
	Deferred tax relating to items that will not be reclassified to profit and loss	7	1	(3)	(10)
	Items that will be reclassified subsequently to profit or loss:				
	Exchange differences on translating the financial statements of foreign operations	97	599	158	1,412
	Net change in fair value of forward contracts designated as cash flow hedges	58	(66)	-	(66)
	Deferred tax relating to items that will be classified to profit and loss	(15)	17	-	17
	Total Other Comprehensive Income for the period/year (net of tax)	**118**	**550**	**167**	**1,394**
9	**Total Comprehensive Income for the period/year (7+8)**	**1,280**	**1,347**	**1,331**	**5,405**
	Profit for the period/year attributable to:				
	Owners of the Parent	1,162	797	1,164	4,011
	Other Comprehensive Income for the period/year attributable to:				
	Owners of the Parent	118	550	167	1,394
	Total Comprehensive Income for the period/year attributable to				
	Owners of the Parent	1,280	1,347	1,331	5,405
10	Paid-up equity share capital (Face value of ₹ 2 each)	481	481	479	481
11	Other equity				30,906
12	**Earnings per equity share (face value of ₹ 2 each)***				
	(a) Basic (in ₹)	4.84	3.32	4.86	16.72
	(b) Diluted (in ₹)	4.81	3.30	4.82	16.62

*Earnings per share is not annualised for quarter ended.

See accompanying notes to the Consolidated Financial Results

INDEGENE LIMITED

INDEGENE LIMITED
CIN No. L73100KA1998PLC102040
Notes to the Statement of Consolidated Financial Results for the quarter ended 30 June 2026

(All amounts in ₹ millions, except share data and where otherwise stated)

1. The above Consolidated Financial Results of Indegene Limited ('the Company' or 'the Parent' or 'the Holding Company') together with its affiliates (collectively 'the Group'), have been prepared in accordance with Indian Accounting Standards ("Ind AS") 34 - Interim Financial Reporting, recognition and measurement principles of Indian Accounting Standards ("Ind AS") prescribed under Section 133 of the Companies Act, 2013, as amended, read with the relevant rules issued thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("the Regulations"). Due to rounding off, the numbers presented throughout may not add up precisely to the totals. "^" in the financial information denote amounts less than ₹ 0.50 million.

2. The above Consolidated Financial Results have been reviewed by the Audit Committee in the meeting held on 28 July 2026 and approved by the Board of Directors at its meeting held on 30 July 2026. The figures for the quarter ended 31 March 2026 are the balancing figures between audited figures in respect of full financial year upto 31 March 2026 and published unaudited year to date figures upto 31 December 2025 being the end of the third quarter of the previous financial year, which were subject to limited review.

3. The Consolidated Financial Results for the quarter and year ended 31 March 2026, are available on the National Stock Exchange of India Limited (URL: www.nseindia.com), the BSE Limited website (URL: www.bseindia.com) and on the Company's website (URL: www.indegene.com/investor-relations).

4. **IPO Fund Utilisation**
During the year ended 31 March 2025, the Company had completed Initial Public Offer (IPO) of 40,766,550 equity shares of face value of ₹ 2 each at an issue price of ₹452 per share (Issue price of ₹422, including a share premium of ₹420 per share, for employee quota towards fresh issue), comprising fresh issue of 16,833,818 shares aggregating to ₹7,600 and offer for sale of 23,932,732 shares by selling shareholders aggregating to ₹10,818. The equity shares of the Company are listed in National Stock Exchange of India Limited (NSE) and BSE Limited (BSE) on 13 May 2024. The Company has received an amount of ₹7,246 [(1)] (net of Company's share of IPO expenses of ₹354, retained in the Public Offer Account to the extent unpaid) from the proceeds of the fresh issue. Out of the Company's shares of IPO expenses ₹319 has been adjusted to securities premium.

The utilization of IPO proceeds of ₹7,246 [(1)] is summarized below:

Particulars	Amount to be utilised as per offer document [(1)]	Amount utilised up to 30 June 2026	Amount un-utilised as of 30 June 2026
Repayment/prepayment of indebtedness of one of the Material Subsidiaries, ILSL Holdings, Inc.[(2)]	3,950	3,950	-
Funding the capital expenditure requirements of our Company and one of our Material Subsidiaries, Indegene, Inc.[(1)]	644	644	-
Technology, Cybersecurity and Cloud infrastructure related cost [(1)]	350	350	-
General corporate purposes and inorganic growth	2,302	2,302	-
Total utilisation of funds	**7,246**	**7,246**	**-**

[(1)] Pursuant to the Special Resolution passed at the Shareholders' Meeting held on 12 August 2025, the Company has revised the objects as per offer document. As per the revised objects, an amount of ₹37 is adjusted from funding capital expenditure requirements towards repayment of indebtedness of ILSL Holdings, Inc for the difference arising due to exchange rate fluctuation as on the date of offer document and as on the date of repayment. Further, an amount of ₹350 is reclassified from funding capital expenditure requirement towards utilization for services including cloud infrastructure and security services, productivity tools, cybersecurity and support services availed by the Company and Indegene Inc. Further, the Board of Directors of the Company has approved the transfer of unutilized IPO expense towards funding capital expenditure requirement by way of Board Resolution passed on 29 January 2026. The unutilized amount of ₹2 has been transferred to the net IPO proceeds, thereby increasing it from ₹7244 to ₹7246 and earmarked for funding capital expenditure requirements at the Company's office premises.

[(2)] During the year ended 31 March 2025, the Company has repaid loan of USD 47.20 Million (₹3,950) outstanding in the books of ILSL Holdings Inc. (material subsidiary), in line with Object 1 of the offer document. The amount of ₹37 utilised over and above the maximum amount specified as per the original amount as per offer document of ₹3,913 was due to exchange rate fluctuation as on the date of offer document and as on the date of payment. The Special Resolution passed on 12 August 2025 revises the object amount to adjust this difference.

Out of the net proceeds, there are no amounts that are unutilised as of 30 June 2026.

5. **Segment information**
During the year ended 31 March 2026, the Group, effective 01 October 2025, has reorganised its segments by merging Brand Activation Segment as part of Enterprise Commercial Solutions in line with the manner in which the chief operating decision maker reviews and evaluates performance of the business of the Group. Pursuant to the above, in accordance with the requirement specified in Ind AS 108, the comparative period information has been recasted to give the effect of this change.

As a consequence , the Group currently has 2 reportable segment i.e., Enterprise Commercial Solutions and Enterprise Medical Solutions.

Segment wise revenue and results are as follows:

Particulars	Quarter ended			Year ended
	30 June 2026	31 March 2026	30 June 2025	31 March 2026
	Unaudited	Unaudited	Unaudited	Audited
1. Segment revenue				
Enterprise Medical Solutions	2,736	2,537	2,132	9,298
Enterprise Commercial Solutions	7,502	7,193	5,211	24,605
Others*	393	304	265	1,202
Total	**10,631**	**10,034**	**7,608**	**35,105**
2. Segment results				
Enterprise Medical Solutions	716	672	576	2,435
Enterprise Commercial Solutions	1,197	1,212	1,099	4,492
Others*	(115)	(163)	(50)	(327)
Total	**1,798**	**1,721**	**1,625**	**6,600**
Unallocable expenses	(52)	(85)	(72)	(410)
Depreciation and amortisation expense	(441)	(418)	(216)	(1,264)
Other income (net)	286	107	221	720
Finance cost	(64)	(71)	(37)	(193)
Exceptional item	-	(203)	-	(203)
Tax expense	(365)	(254)	(357)	(1,239)
Profit after Tax	**1,162**	**797**	**1,164**	**4,011**

**Others mainly comprises of consultancy and clinical business.*

INDEGENE LIMITED

(All amounts in ₹ millions, except share data and where otherwise stated)

Notes on Segment information
Operating segments are identified as components of an enterprise for which discrete financials information is evaluated regularly by the chief operating decision maker in deciding how to allocate resources and assessing performance. The Group's chief operating decision maker is the Chief Executive Officer and Executive Director.

Assets and liabilities used in the Group's business are not identified to any of the operating segments, as these are used interchangeably between segments. Management believes that it is currently not practicable to provide segment disclosures relating to total assets and liabilities since a meaningful segregation of the available data is onerous.

6. **Exception Item: Litigation Expenses**

During the year 2020-21, Indegene Inc. (a subsidiary of the Company) was named in a class action lawsuit filed in the U.S. District Court of New Jersey, alleging non-compliance with the Telephone Consumer Protection Act of 1991 ('TCPA') by sending unsolicited fax advertisements without the recipient's prior express invitation or permission.

Plaintiff initiated this matter through the filing of its Class Action Complaint against Indegene, Inc., Indegene Encima Inc., Indegene Wincere Inc., and Indegene Healthcare, LLC (collectively, "Indegene" or "Defendants") seeking the Court to award actual monetary loss from the alleged TCPA violations in an amount to be proven in Court or the sum of USD 500 for each violation, whichever is greater, and that the Court award treble damages of USD 1,500 if the violations are deemed wilful or knowing. Additionally, the Plaintiff seeks the Court award pre-judgment interest and costs, to be determined upon presentation of suitable evidentiary support.

During the year ended 31 March 2026, the matter progressed to mediation and the Group agreed in principle to a mediator-proposed settlement framework providing for a maximum settlement amount of ₹417 (USD 4.72 million). The proposed settlement is structured as a claims-made arrangement, whereby the actual outflow is contingent upon valid claims submitted by eligible class members, and unclaimed amounts, if any, revert to the Group. The proposed settlement remains subject to execution of definitive agreements and approval by the Court.

Based on the status of the proceedings and Group's assessment, supported by external legal advice, the Group during the year ended 31 March 2026 concluded that a present obligation exists and that an outflow of economic resources was probable and which could be reliably estimated. Accordingly, the Group recognised a provision of ₹203 (USD 2.30 million), including estimated legal costs, representing best estimate of the expenditure required to settle the obligation which has been disclosed as an exceptional item in the results for the quarter and year ended 31 March 2026 and the Group does not estimate any change in the amount of provision as on 30 June 2026. The term sheet for the settlement agreement dated 25 May 2026 has been duly signed , which will be formalizing into the Settlement agreement post approval by the court.

7. The Board of Directors, in its meeting on 29 April 2026, have proposed a final dividend of ₹2.25 per equity shares for the financial year ended 31 March 2026. The proposal is subject to the approval of shareholders at the ensuing Annual General Meeting and if approved, would result in a cash outflow of approximately ₹542.

INDEGENE LIMITED

by Order of the Board of
INDEGENE LIMITED

Bengaluru
30 July 2026

Manish Gupta
Chief Executive Officer and Executive Director

Deloitte
Haskins & Sells

Chartered Accountants
Prestige Trade Tower, Level 19
46, Palace Road, High
Grounds, Bengaluru – 560 001
Karnataka, India

Tel: +91 (80) 6188 6000
Fax: +91 (80) 6188 6011

INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM STANDALONE FINANCIAL RESULTS

TO THE BOARD OF DIRECTORS OF
INDEGENE LIMITED

1. We have reviewed the accompanying Statement of Unaudited Standalone Financial Results of **INDEGENE LIMITED** ("the Company"), for the quarter ended June 30, 2026 ("the Statement") attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations").

2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For **Deloitte Haskins & Sells**
Chartered Accountants
Firm's Registration No. 008072S

Sathya P Koushik
Partner
Membership No.: 206920
UDIN: 26206920LQMXIH4231

Place: Bengaluru
Date: July 30, 2026

Indegene Limited
CIN No. L73100KA1998PLC102040
Statement of Standalone Financial Results for the quarter ended 30 June 2026

(All amounts in ₹ millions, except share data and where otherwise stated)

Sl. No.	Particulars	Quarter ended			Year ended
		30 June 2026	31 March 2026	30 June 2025	31 March 2026
		Unaudited	Unaudited (Refer note 2)	Unaudited	Audited
1	**Income**				
	(a) Revenue from operations	3,407	3,682	2,556	12,206
	(b) Other income (net)	339	61	321	783
	Total income	**3,746**	**3,743**	**2,877**	**12,989**
2	**Expenses**				
	(a) Employee benefits expense	2,217	2,134	1,816	7,952
	(b) Finance costs	27	31	17	87
	(c) Depreciation and amortisation expense	114	109	73	363
	(d) Other expenses	588	517	373	1,773
	Total expenses	**2,946**	**2,791**	**2,279**	**10,175**
3	**Profit before tax (1-2)**	**800**	**952**	**598**	**2,814**
4	**Tax expense**				
	- Current tax	178	260	145	707
	- Deferred tax	23	(29)	2	(12)
	Total tax expense	**201**	**231**	**147**	**695**
5	**Profit for the period/year (3-4)**	**599**	**721**	**451**	**2,119**
6	**Other Comprehensive Income (OCI), net of taxes**				
	Items that will not be reclassified subsequently to the statement of profit or loss:				
	Remeasurement of defined benefit obligation	(29)	(1)	12	41
	Deferred tax relating to items that will not be reclassified to profit and loss	7	1	(3)	(10)
	Items that will be reclassified subsequently to profit or loss:				
	Exchange differences on translating the financial statements of foreign operation	-	-	-	-
	Net change in fair value of forward contracts designated as cash flow hedges	40	(79)	-	(79)
	Deferred tax relating to items that will be classified to profit and loss	(10)	20	-	20
	Total Other Comprehensive (Loss)/Income for the period/year (net of tax)	**8**	**(59)**	**9**	**(28)**
7	**Total comprehensive income for the period/year (5+6)**	**607**	**662**	**460**	**2,091**
8	Paid-up equity share capital (Face value of ₹ 2 each)	481	481	479	481
9	Other equity				20,324
10	**Earning per equity share (face value ₹ 2 each)***				
	(a) Basic (in ₹)	2.49	3.00	1.88	8.83
	(b) Diluted (in ₹)	2.48	2.98	1.87	8.78

*Earnings per share is not annualised for quarter ended.

See accompanying notes to the Standalone financial results

INDEGENE LIMITED

Indegene Limited
CIN No. L73100KA1998PLC102040
Notes to the Statement of Standalone Financial Results for quarter ended 30 June 2026

(All amounts in ₹ millions, except share data and where otherwise stated)

1. The above Standalone Financial Results of the Indegene Limited ('the Company'), have been prepared in accordance with Indian Accounting Standards ("Ind AS") 34 - Interim Financial Reporting, recognition and measurement principles of Indian Accounting Standards ("Ind AS") prescribed under Section 133 of the Companies Act, 2013, as amended, read with the relevant rules issued there under and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("the Regulations"). Due to rounding off, the numbers presented throughout may not add up precisely to the totals. "^" in the financial information denote amounts less than ₹ 0.50 million.

2. The above Standalone Financial Results have been reviewed by the Audit Committee held on 28 July 2026 and approved by the Board of Directors at its meeting held on 30 July 2026. The figures for the quarter ended 31 March 2026 are the balancing figures between audited figures in respect of full financial year upto 31 March 2026 and published unaudited year to date figures upto 31 December 2025 being the end of the third quarter of the previous financial year, which were subject to limited review.

3. The Standalone Financial Results for the quarter ended 30 June 2026, are available on the National Stock Exchange of India Limited (URL: www.nseindia.com), the BSE Limited website (URL: www.bseindia.com) and on the Company's website (URL: www.indegene.com/investor-relations).

4 During the year ended 31 March 2025, the Company had completed Initial Public Offer (IPO) of 40,766,550 equity shares of face value of ₹ 2 each at an issue price of ₹452 per share (Issue price of ₹422, including a share premium of ₹420 per share, for employee quota towards fresh issue), comprising fresh issue of 16,833,818 shares aggregating to ₹7,600 and offer for sale of 23,932,732 shares by selling shareholders aggregating to ₹10,818. The equity shares of the Company are listed in National Stock Exchange of India Limited (NSE) and BSE Limited (BSE) on 13 May 2024. The Company has received an amount of ₹7,246[1] (net of Company's share of IPO expenses of ₹354, retained in the Public Offer Account to the extent unpaid) from the proceeds of the fresh issue. Out of the Company's shares of IPO expenses ₹319 has been adjusted to securities premium.

The utilization of IPO proceeds of ₹7,246 [1] is summarized below:

Particulars	**Amount to be utilised as per offer document [1]**	**Amount utilised up to 30 June 2026**	**Amount un-utilized as of 30 June 2026**
Repayment/prepayment of indebtedness of one of the Material Subsidiary, ILSL Holdings, Inc. [2]	3,950	3,950	-
Funding the capital expenditure requirements of the Company and one of the Material Subsidiary, Indegene, Inc[1].	644	644	-
Technology, Cybersecurity and Cloud infrastructure related cost [1].	350	350	-
General corporate purposes and inorganic growth	2,302	2,302	-
Total	**7,246**	**7,246**	**-**

[1] Pursuant to the Special Resolution passed at the Shareholders' Meeting held on 12 August 2025, the Company has revised the objects as per offer document. As per the revised objects, an amount of ₹37 is adjusted from funding capital expenditure requirements towards repayment of indebtedness of ILSL Holdings, Inc for the difference arising due to exchange rate fluctuation as on the date of offer document and as on the date of repayment. Further, an amount of ₹350 is reclassified from funding capital expenditure requirement towards utilization for services including cloud infrastructure and security services, productivity tools, cybersecurity and support services availed by the Company and Indegene Inc. Further, the Board of Directors of the Company has approved the transfer of unutilized IPO expense towards funding capital expenditure requirement by way of Board Resolution passed on 29 January 2026. The unutilized amount of ₹2 has been transferred to the net IPO proceeds, thereby increasing it from ₹7,244 to ₹7,246 and earmarked for funding capital expenditure requirements at the Company's office premises.

[2] During the year ended 31 March 2025, the Company has repaid loan of USD 47.20 Million (₹3,950) outstanding in the books of ILSL Holdings Inc. (material subsidiary), in line with Object 1 of the offer document. The amount of ₹37 utilised over and above the maximum amount specified as per the original amount as per offer document of ₹3,913 was due to exchange rate fluctuation as on the date of offer document and as on the date of payment. The Special Resolution passed on 12 August 2025 revises the object amount to adjust this difference.

Out of the net proceeds, there are no amounts that are unutilised as of 30 June 2026.

5 The Company publishes this Standalone Financial Results along with the Consolidated Financial Results. In accordance with Ind AS 108, Operating Segments, the Company has disclosed the segment information in the Consolidated Financial Results.

6 The Board of Directors, in its meeting on 29 April 2026, have proposed a final dividend of ₹2.25 per equity shares for the financial year ended 31 March 2026. The proposal is subject to the approval of shareholders at the ensuing Annual General Meeting and if approved, would result in a cash outflow of approximately ₹542.

By Order of the Board of
INDEGENE LIMITED

INDEGENE LIMITED

Bengaluru
30 July 2026

Manish Gupta
Chief Executive Officer and Executive Director

Date: - July 30, 2026

The Declaration by CFO regarding audit report with unmodified opinion

I, Suhas Prabhu, Chief Financial Officer of the Company, hereby declare, that the Company's Statutory Auditors, Deloitte Haskins & Sells, Chartered Accountants, Firm's Registration No. 008072S, have submitted an unmodified opinion / unqualified opinion on the unaudited Financial Results for the quarter ended 30 June 2026.

For Indegene Limited

Suhas Prabhu
Chief Financial Officer

indegene®

Registered office

Indegene Limited,
Third Floor, Aspen G-4 Block, Manyata Embassy Business Park (SEZ), Outer Ring Road, Nagawara,
Bengaluru- 560 045, Karnataka, India

Phone : +91 80 4674 4567, +91 80 4644 7777
www.indegene.com

CIN: L73100KA1998PLC102040